ALK and neuroblastoma: Primary resistance to crizotinib and early-generation ALK inhibitors represents a major obstacle for common ALK hotspot mutations in neuroblastoma (for example, F1174L and F1245C)11,15–18, supporting the need for next-generation ALK TKIs with improved selectivity and potency against neuroblastoma de novo resistant ALK mutations.